Emerging Treatments for Bipolar Depression CME

Paul E. Keck, Jr., MD

July 23, 2004

TOP READ in the past 7 days

Efficacy of atypical antipsychotics in bipolar disorder

This paper provides an overview of current knowledge on atypical antipsychotics
as an alternative and adjunct to conventional mood stabilisers in patients with
bipolar disorder, current evidence on the benefits of olanzapine and quetiapine,
approaches to treating mixed states and rapid cycling, refractory episodes, mania
and depression...Full Story

Most read Psychiatry news in the past 7 days

Papers and articles, pertaining to Psychiatry, most read by your colleagues in the past 7 days

• Current Options in the Management of Olanzapine-Associated Weight Gain

(February) (Ann Pharmacother)
• Randomized double-blind comparison of serotonergic (Citalopram) versus
noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform,
DSM-IV-TR pain disorder (Eur J Pain)
• Newer antidepressants in pregnancy: prospective outcome of a case series
(Reprod Toxicol)
• Anticonvulsants and antipsychotics in the treatment of bipolar disorder (Rev
Bras Psiquiatr)
• Rhabdomyolysis connected with the use of bupropion (Scand J Prim Health
Care)
• Nightmares in patients with Alzheimer's disease caused by donepezil
(Nervenarzt)
• Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to
Venlafaxine or Placebo (Neuropsychopharmacology)
• Multiple-Dose Pharmacokinetics of Fluvoxamine in Children and Adolescents (J
Am Acad Child Adolesc Psychiatry)
• Plasma levels of leptin and endogenous immune modulators during treatment
with carbamazepine or lithium (Psychopharmacology (Berl))
• Cholinesterase inhibition as a possible therapy for delirium in vascular dementia:
a controlled, open 24-month study of 246 patients (Am J Alzheimers Dis Other
Demen)

More news...

In the past 7 days, 75 papers and articles pertaining to Psychiatry were added to the DG database. For a full
list click here.

Most read Psychiatry news in the past 3 months

Papers and articles, pertaining to Psychiatry, most read by your colleagues in the past 3 months

• Neurobiology and pharmacotherapy of social phobia (L' Encephale)

• Potential benefits of quetiapine in the treatment of substance dependence
disorders (J Psychiatry Neurosci)
• Aripiprazole and neuroleptic malignant syndrome (Int Clin Psychopharmacol)
• Clozapine, 10 years after - A clinical review (L' Encephale)

• Antidepressant pharmacotherapy in the treatment of depression in the very old: a

randomized, placebo-controlled trial (Am J Psychiatry)
000000000000000000000000000000000000000000000000000000000000000000000

Newer antidepressants in pregnancy: prospective outcome of a

case series.

Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI, Unsal M.

Department of Family Medicine, School of Medicine, Karadeniz Technical

University, TR-61187 Trabzon, Turkey.

Antidepressant drug choice in pregnancy is a complex problem especially

for new drugs. Among 590 cases exposed to drugs during pregnancy who
were followed by our center, 21 cases used newer antidepressants, i.e.,
venlafaxine, mirtazapine, nefazodone. We present the gestational findings
and fetal outcomes of these cases. Ten cases had used venlafaxine, one case
had used both venlafaxine and mirtazapine, eight had used mirtazapine alone
or with some other drugs and two had used nefazodone, in the first trimester.
Of the 21 cases, 17 (80.9%) had healthy babies, 3 (14.3%) decided to
terminate the pregnancy, and 1 (4.8%) spontaneous abortion was observed in
a case exposed to mirtazapine, alprazolam, diazepam and trifluoperazine. All
obstetrical findings were normal during the pregnancy of each case. No
congenital abnormality and developmental problem was observed in the
babies followed up for 12 months. The aim of the present study is to
contribute the data to the limited knowledge available in the literature
regarding human pregnancy.

PMID: 15501389 [PubMed - in process]

Show:

Write to the
Help Desk
NCBI | NLM
| NIH
Department
of Health &
Human
Services
Privacy
Statement |
Freedom of
Information
Act |
Disclaimer